IngredientsGentiana is a genus of flowering plants belonging to the gentian family (Gentianaceae), the tribe Gentianeae, and the monophyletic subtribe Gentianinae. Gentiana macrophylla, the large-leaf gentian, is called qin jiao (秦艽) in Chinese. The species was formally described by the German botanist Peter Simon Pallas and bears the full authority designation Gentiana macrophylla Pall. It is also known as bigleaf gentian.
Botanical synonyms include G. straminea, G. crassiaulis, and G. dahurica. This naming complexity is significant in practice: in the Chinese Pharmacopoeia, the roots of four plants from the genus Gentiana — Gentiana macrophylla Pall., Gentiana crassicaulis Duthie., Gentiana straminea Maxim., and Gentiana dahurica Fisch. — are all recorded as the original source materials of "Qin-Jiao." A staple in traditional Chinese medicine, Gentiana macrophylla was first documented in Shennong's Herbal Classic, and the medicinal part of the plant is its dried root.
G. macrophylla is found in China, Kazakhstan, Mongolia, and Russia. G. macrophylla grows in China and Siberia. Within China, the Qinling Mountain range is among the primary producing areas; both wild and cultivated G. macrophylla samples have been collected from the Qinling Mountains, China. Some populations also occur on the Tibetan Plateau, where the plant is found in the high alpine lands at altitudes between 2,400 and 3,500 metres.
Owing to its high medical value, uncontrolled exploitation has led to wild resources being extremely scarce, and it is listed by the Chinese government as a third-class protected wild herb. At present, "Qinjiao" has third-class protection and is on the List of National Key Protected Wild Herbs in China. The increasing demand for this material has led to the widespread cultivation of the plant.
Radix Gentianae Macrophyllae, commonly known as Qinjiao (秦艽 in Chinese), is the dried root of medicinal plants belonging to the Gentianaceae family and Gentiana genus. The Chinese Pharmacopoeia specifies quality thresholds for the crude drug: the total content of gentiopicroside and loganic acid in qualified Gentiana macrophylla samples should be greater than 2.5%.
The medicinal part of the plant is its dried root. Unlike the intensely bitter Gentiana lutea, G. macrophylla has a gentler taste and is typically used in decoctions, capsules, or patent formulas. Classical prescriptions using Radix Gentianae Macrophyllae as the monarch drug primarily include Da Qinjiao decoction (DQJD), Qinjiao Biejia powder (QBP), Qinjiao Cangzhu decoction (QCD), and Duhuo Jisheng decoction (DJD). The powdered root, hydroalcoholic extracts, and standardized tablet preparations are all encountered in both traditional and modern integrative medicine contexts. The herb contains flavonoids, iridoids, secoiridoids, polysaccharides, and xanthones, with a wide spectrum of pharmacological activity.
Qinjiao is an ancient Chinese herbal medicine and has been described and recorded in several ancient Chinese medicine monographs including Shen Nong's Herbal Classic (Han Dynasty, Shen Nong Ben Cao Jing) and the Compendium of Materia Medica (Ming Dynasty, Ben Cao Gang Mu), and also in the Chinese Pharmacopoeia. Over 2,000 years, Qinjiao has been utilised to treat a wide range of diseases, including hypertension, osteoarthritis, and especially rheumatism.
Qinjiao has been described and recorded in several Chinese medicine monographs: Shen Nong's Herbal Classic (Han Dynasty), Commentaries on the Illustrations (Song Dynasty, Tu Jing Ben Cao), An Illustrated Book on Plants (Qing Dynasty, Zhi Wu Ming Shi Tu Kao), and especially the Compendium of Materia Medica (Ming Dynasty, Ben Cao Gang Mu), which described Qinjiao as a middle-grade medicine. Since the Tang Dynasty, G. macrophylla Pall. has been recognised as the primary source of this medicinal material, and historical research has firmly established its origin.
G. macrophylla is characterised by a pungent, bitter, and neutral taste, and is traditionally used for dispelling wind-dampness, clearing damp-heat, alleviating arthralgia pain, reducing deficiency heat, and treating a variety of conditions including rheumatism, arthralgia, stroke-related hemiplegia, muscle spasms, aching joints, damp-heat jaundice, bone steaming hot flashes, and infantile malnutrition fever.
In traditional Chinese medicine, G. macrophylla (qin jiao) is considered to have a neutral nature and a bitter, pungent taste. It is associated with the liver, stomach, and gallbladder. It is used as a tonic for the digestive system, and to treat arthritis, chronic low-grade fever, jaundice, hepatitis, and constipation.
According to Chinese medicine principles, Qinjiao is described as bitter and a little astringent with a distinct smell. It has the medicinal potencies of dispelling winds, eliminating dampness, promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat and asthenic fever, diuresis, and activating Qi (energy).
In TCM, G. macrophylla is categorised as a wind-damp dispelling herb. The Chinese use G. macrophylla (Qin Jiao) alongside G. scabra (Long Dan Cao), attributing slightly different characteristics to each. It is often combined with herbs like fang feng (siler), dang gui (angelica), and bai shao (white peony) in traditional formulas designed to relieve wind-dampness and nourish the blood.
Gentiana macrophylla Pall. is a traditional Tibetan medicinal herb with more than 2,000 years of history, and is a member of the Gentianaceae family; it has the function of clearing heat, relieving deficiency heat, detoxification, relaxing meridians, dispelling dampness and rheumatism, and treating jaundice.
It is a common Tibetan medicinal herb used for the treatment of tonsillitis, urticaria, and rheumatoid arthritis, while the flowers of G. macrophylla have been traditionally treated as an anti-inflammatory agent to clear heat in Mongolian medicine. In Mongolia, G. macrophylla is among the eight species of Gentiana with recorded medicinal significance.
In traditional medicine texts, Gentiana's different exclusive forms of preparations are cited as effective for treatment of some disorders such as menstrual over-bleeding, conjunctivitis, vitiligo, animal venom poisoning, injuries, infected wounds, pain and swelling of liver, spleen, stomach, and sprains of muscles. There are some activities that are the same in traditional and modern medicine, such as anti-inflammatory, hepatoprotective, and diuretic effects.
Root and leaves of G. scabra and Gentiana macrophylla have been used in Chinese herbalism for over 2,000 years as an excellent tonic for the digestive system, working on the stomach, liver, and gallbladder. Historically, the dried root was typically prepared as a water decoction, though alcohol macerations and powders were also employed. G. macrophylla contains bitter compounds that have been extensively used in Chinese herbal medicine in the treatment of a wide range of diseases, including diabetes, apoplexy, paralysis, and stomachache.
In total, 248 compounds have been identified in Radix Gentianae Macrophyllae and related plants, including cycloeneether terpene glycosides (29.44%), triterpenoids (11.29%), lignans (2.82%), flavonoids (17.34%), alkaloids (5.24%), and phenolic acids/benzoic acids (8.47%). This enumeration from a 2025 systematic review represents the most comprehensive chemical census to date. An earlier review noted nearly 166 compounds including iridoids, triterpenes, flavonoids, sterols, and alkaloids identified from the roots and flowers of G. macrophylla, G. straminea, G. crasicaulis, G. daurica, G. tibetica, G. siphonantha, and G. waltonii.
Iridoids are the primary active components of G. macrophylla. Secoiridoid glycosides and their derivatives are the primary active components of G. macrophylla and have been demonstrated to be effective as anti-inflammatory agents.
Chemical analyses of the roots of G. macrophylla have identified iridoid glycosides such as gentiopicroside, amarogentin, sweroside, and loganic acid as major constituents. Gentiopicroside, an abundant and indicative ingredient in Qin-jiao, is the most important active component of total secoiridoid glycosides and has significant anti-inflammatory, analgesic, and antibacterial properties, as well as biological activity for treating osteoarthritis and strengthening gastric motility.
Gentiopicroside (also called gentiopicrin) is the flagship compound: gentiopicroside is an iridoid glucoside and one of the primary compounds enriched in Gentiana macrophylla Pall. roots. Gentiopicroside is a bioactive iridoid glycoside isolated from Gentianaceae plants.
Amarogentin is another key iridoid. Amarogentin is one of the key bitter constituents of the plant and, although present in smaller quantities than gentiopicroside, it is approximately 3,000 times more bitter and is thought to be among the most bitter substances known, having been tasted at dilutions of 1:50,000.
Among Mongolian Plateau Gentiana species, gentiopicroside and swertiamarin are the most studied monomeric compounds.
Triterpenoids constitute approximately 11% of identified compounds. Notable members include roburic acid (also referred to in some sources as Apocynum venetum acid or RBA). Roburic acid (RBA), an ingredient from the anti-RA herb Gentiana macrophylla Pall., has been shown to display strong anti-inflammatory activity. Ursolic acid, oleanolic acid, and β-sitosterone have also been identified in some Qinjiao species, particularly G. dahurica.
The main bioactive components isolated from the genus include iridoids (e.g., gentiopicroside, swertiamarin, and sweroside), xanthones (e.g., isogentisin, bellidifolin, and mangiferin), and flavonoids (e.g., isoorientin and isovitexin). Flavonoids represent approximately 17% of identified compounds in Radix Gentianae Macrophyllae.
Chemical constituents include gentianine, gentianidine, gentiopicroside, and gentianol. Gentianine and gentianidine are monoterpene alkaloids that form part of the alkaloid fraction, which represents approximately 5% of total identified compounds.
It has been observed that secoiridoids such as loganic acid, gentiopicroside, and swertiamarin are richer in the species Gentiana crassicaulis, while flavonoids (morroniside) and triterpenoids (roburic acid, ursolic acid, oleanolic acid, β-sitosterone) are richer in Gentiana dahurica. This inter-species variation has practical implications for quality control and clinical equivalence across the four official Qinjiao source species.
The anti-inflammatory effects of Gentianae Radix et Rhizoma primarily target the NF-κB (Nuclear Factor κB) signalling axis. Experimental evidence confirms that its active component, gentiopicroside, inhibits IκB kinase β (IKKβ) phosphorylation. This leads to the blockade of NF-κB nuclear translocation and subsequent downregulation of key inflammatory mediators such as COX-2, TNF-α, and IL-6.
Concurrently, gentiopicroside suppresses the activation of JNK and p38 within the MAPK pathway, further reducing the production of pro-inflammatory cytokines. In rheumatoid arthritis models, this mechanism significantly alleviates synovial inflammation and joint destruction.
Gentiopicroside has been shown to inhibit pathways of IL-1β signal transduction in rat chondrocytes, including p38, ERK, and JNK, while also showing inhibition of IL-1β-induced release of MMPs and increasing Collagen type II expression.
Gentiopicroside modulates key signalling pathways such as NF-κB and MAPK to suppress pro-inflammatory cytokines and oxidative stress. It also activates the Keap1-Nrf2 pathway to enhance cellular antioxidant defences and exhibits direct free radical scavenging capabilities.
In animal models of gastric mucosal injury, oral administration of gentiopicroside significantly increased heat shock protein-70 and glutathione levels and superoxide dismutase activity, normalised epidermal growth factor and vascular endothelial growth factor levels, and decreased the levels of tumour necrosis factor-α, interleukin-6, malondialdehyde, and myeloperoxidase activity in gastric tissue.
The primary compounds responsible for the anti-inflammatory and hepatoprotective effects of Gentiana plants are iridoids and secoiridoids. Gentiopicroside can alleviate liver injury caused by alcohol, D-galactosamine, or lipopolysaccharide by reducing liver function impairment, improving hepatic lipid disorders, and inhibiting oxidative stress and inflammation.
Gentiana macrophylla can decrease the activities of ALT and AST in the serum of CCl4-induced acute liver injury mice, as well as MDA in the liver, and also enhances the activity of SOD. Following the administration of this extract, the damaged hepatic tissue structure was restored and the amount of collagen deposition decreased.
The main active component in Gentiana macrophylla is primarily gentiopicroside. Orally administered root extract markedly lowered prostaglandin E2 (PGE2) levels in inflammatory tissues compared to control and prednisone groups, suggesting that inhibition of the COX-2 enzyme most likely occurred.
In pre-clinical studies of rheumatoid arthritis, gentiopicroside significantly reduced joint swelling, arthritis scores, inflammatory cell infiltration, and bone erosion. It worked by suppressing the ROS-NF-κB-NLRP3 inflammasome pathway, reducing key inflammatory markers including TNF-alpha, IL-1beta, and IL-6.
In neurodegenerative disease models, gentiopicroside reduces amyloid-β accumulation and dopaminergic neuron loss in Alzheimer's and Parkinson's disease models, respectively.
This is the most extensively studied application of G. macrophylla in the scientific literature, though the overwhelming majority of evidence remains preclinical.
Animal studies: Acute treatment of rheumatoid rats with an extract from the roots of Gentiana macrophylla produced a significant inhibitory effect on rheumatoid arthritis. When rats were administered the extract orally at a daily dose of 100 mg/kg body weight, prostaglandin E2 (PGE2) levels in the inflammatory tissues, sole thickness, and ankle circumferences were significantly decreased. The anti-inflammatory activity observed was comparable to that observed in prednisone.
Gentiopicroside is an iridoid glucoside derived from G. macrophylla Pall., used in traditional Chinese medicine to treat RA. A study was designed to explore the ability of gentiopicroside to combat RA using TNF-α-stimulated human RA fibroblast-like synoviocytes in vitro and a rat adjuvant-induced arthritis model in vivo. Gentiopicroside was found to significantly reduce the swelling of joints and arthritic index scores, with corresponding reductions in synovial inflammatory cell infiltration, synovial hyperplasia, and bone erosion in treated rats.
Iridoid glycosides extracted from G. macrophylla flowers (containing gentiopicroside, sweroside, swertiamarin, and loganic acid) were tested in a collagen-induced arthritis rat model. The extract significantly reduced paw edema, arthritis scores, and spleen/thymus indices, and inhibited pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, as well as iNOS and COX-2 expression.
Osteoarthritis (in vitro): Gentiopicroside exhibited a potent protective effect on IL-1β-induced inflammation response in rat articular chondrocytes. The MTT assay demonstrated that 50, 500, and 1,500 μg/mL of gentiopicroside exhibited no significant toxicity to chondrocytes after 24 hours.
Human/clinical evidence: Direct randomised controlled trials using G. macrophylla alone as an intervention in human arthritis populations are not currently well-represented in the indexed literature. Gentianae Macrophyllae Radix plays an important role in the modern integrated treatment of rheumatic and immune diseases, primarily as a component of multi-herb TCM formulas rather than as a single-agent studied in isolation. Robust clinical trials in humans are limited; most existing studies are either in vitro or involve animal models, and more rigorous human-based research is needed to definitively confirm the health benefits.
Human case series: In an investigation of 58 patients with reflex sympathetic dystrophy (RSD) with stagnation of vital energy and blood stasis, G. macrophylla was demonstrated to have beneficial effects in the treatment of RSD by improving blood circulation and removing blood stasis. This represents an observational report rather than a controlled trial.
Evidence strength: Moderate at the pre-clinical level for anti-inflammatory and anti-arthritic mechanisms; weak at the human clinical level due to the absence of large-scale RCTs using G. macrophylla as a monotherapy.
Animal and in vitro studies: Gentiana species including G. macrophylla are known to protect and enhance hepatocyte viability via their antioxidant, anti-inflammatory, and bitter components including amarogentin, gentianine, iso-orientin, swertiamarin, gentiopicroside, and sweroside.
Modern pharmacological research has shown that gentiopicroside exhibits antioxidant, anti-inflammatory, and analgesic properties. It can inhibit both acute and chronic inflammatory responses, significantly reduce serum transaminase levels in various models of acute and chronic liver injury, mitigate liver tissue damage (such as necrosis, swelling, and steatosis), and promote liver protein synthesis.
Other Gentiana species including Gentiana macrophylla Pall. have shown hepatoprotective effects against liver injury induced by carbon tetrachloride, ethanol, and acetaminophen.
Evidence strength: Preliminary to moderate; based on animal models and in vitro experiments. One study showed that sweroside reduces the level of ALT in patients who suffer from hepatitis, providing a limited human data point. Rigorous clinical trials specifically isolating G. macrophylla's hepatoprotective effect in humans have not been identified in the indexed literature.
Animal studies: The roots of Gentiana macrophylla, known as Qinjiao, have been used for centuries to treat systemic lupus erythematosus. A study investigated whether Gentiana macrophylla exhibits anti-apoptotic effects in cholesterol-induced cardiac abnormalities associated with SLE, conducted on NZB/W F1 mice fed a high-cholesterol diet, evaluating the morphology of the left ventricle tissues and apoptotic biomarkers. The results revealed that G. macrophylla significantly reduced the cholesterol-aggravated apoptosis of the left ventricle in NZB/W F1 mice by suppressing both intrinsic and extrinsic apoptotic pathways.
Evidence strength: Preliminary (animal model only). No human clinical data for this indication has been identified in the indexed literature.
Radix Gentianae Macrophyllae has been used for the treatment of various diseases such as arthritis, stroke, facial paralysis, and scapulohumeral periarthritis in China since ancient times. Clinical application of Radix Gentianae Macrophyllae in arthritis, stroke, and other diseases has been summarised in systematic reviews.
In neurodegenerative disease models, gentiopicroside reduces amyloid-β accumulation and dopaminergic neuron loss in Alzheimer's and Parkinson's disease models, respectively.
Evidence strength: Traditional use is well-documented. Scientific evidence for neuroprotection is largely from preclinical (animal and cell) models. Controlled clinical trials in stroke patients using G. macrophylla as the principal intervention have not been identified in indexed sources.
A study evaluated the protective effect of gentiopicroside against ethanol-induced gastric mucosal injury in mice. Mice were pre-administered gentiopicroside by intragastric administration once a day for 3 consecutive days, then gastric ulcers were induced with 70% ethanol. Gentiopicroside administered orally ameliorated the severity of gastric mucosal alterations.
In a colitis model, gentiopicroside treatment significantly attenuated damage to the intestinal mucosa and symptoms, including weight loss and diarrhoea. This was associated with decreased mRNA expression of inflammatory markers including TNF-α, IL-1β, IL-6, as well as a reduction in the overexpression of COX-2 and iNOS proteins in the colon.
The root of several Gentiana species is used as a bitter tonic that excites the flow of gastric juices, promoting the appetite and aiding in digestion.
Evidence strength: Preclinical (animal model) evidence is moderately consistent. No specific human clinical trials for this indication have been identified in indexed literature.
Gentiopicroside has been shown to possess analgesic, anti-inflammatory, anti-cancer, lipid-regulating, and antidepressant properties. These antidepressant observations are derived from preclinical studies. Gentiopicroside possesses a wide spectrum of pharmacological properties, including hepatoprotective, anti-arthritic, analgesic, antidiabetic, anticancer, and neuropsychopharmacological activities.
Evidence strength: Preliminary (animal/in vitro only for neuropsychopharmacological effects). No human clinical data identified.
Gentiopicroside also has antitumor activity by inducing apoptosis and inhibiting the proliferation of cancer cells. Extracts of G. macrophylla have been studied in treating various diseases; for example, research showed that G. macrophylla alleviated cholesterol-aggravated cardiac apoptosis in systemic lupus erythematosus. Separate research has explored G. macrophylla flavonoids in non-small cell lung cancer cell lines under hypoxic conditions, at the laboratory stage only.
Evidence strength: Strictly preliminary (in vitro and animal); no human oncological data available from identified sources.
Compounds and extracts isolated from the Gentiana genus show a wide range of protective activities including hepatic protection, gastrointestinal protection, cardiovascular protection, immunomodulation, joint protection, pulmonary protection, bone protection, and reproductive protection.
The following dosages are reported in source materials and do not constitute recommendations.
According to Chinese medicine principles, traditionally the dried roots are chosen as the principal drug form. In classical formulas, the daily dose of the root in decoction is typically within the range recorded in pharmacopoeial texts; for the powdered form, 1–3 grams is cited, and the powder can be mixed with water, a suitable decoction, wine, or alcohol for topical application.
In a rat model of rheumatoid arthritis, oral administration of the Gentiana macrophylla extract at a daily dose of 100 mg/kg body weight significantly decreased PGE2 levels in inflammatory tissues.
In pharmacokinetic studies in rats, gentiopicroside from orally administered decoctions of Gentiana macrophylla was compared with gentiopicroside administered alone at 150 mg/kg orally and 30 mg/kg intravenously. After oral administration of gentiopicroside alone, it was absorbed quickly and reached a maximum plasma concentration (Cmax) of 5.78 ± 2.24 μg/mL within 0.75 ± 0.62 hours, with a plasma half-life of 3.35 ± 0.76 hours.
To ensure quality, the Chinese Pharmacopoeia recommends that, in addition to the HPLC method, morphological, microscopic, and thin-layer chromatography identification techniques should also be performed. The total content of gentiopicroside and loganic acid in qualified Gentiana macrophylla samples should be greater than 2.5%.
In TCM systems, the clinical application of Radix Gentianae Macrophyllae exhibits three distinct characteristics: diversity in formula combinations, specificity in processing methods, and clarity in clinical symptom indications. The classical prescriptions using Radix Gentianae Macrophyllae as the monarch drug primarily include Da Qinjiao decoction (DQJD), Qinjiao Biejia powder (QBP), Qinjiao Cangzhu decoction (QCD), and Duhuo Jisheng decoction (DJD).
When elevated doses are given, no major toxic effects have been identified in in vivo studies regarding the Gentiana genus. Amarogentin at a dose of 1,000 mg/kg did not produce any signs of toxicity for up to 14 days in C57BL/6 mice. Gentiana macrophylla Pall. root extract caused no mortality and no abnormal performance at the dose of 500 mg/kg in Kunming mice after 48 hours.
Natural products from Gentiana plants show no significant animal toxicity, cytotoxicity, or genotoxicity based on reported in vivo and in vitro studies. Crude extracts of Gentiana show a broad spectrum of pharmacological activities and these extracts exhibit no apparent toxicity in in vivo and in vitro studies.
The MTT assay demonstrated that 50, 500, and 1,500 μg/mL of gentiopicroside exhibited no significant toxicity to chondrocytes after 24 hours. This finding is specific to chondrocyte culture and cannot be generalised to all cell types or systemic exposure.
Gentian is contraindicated in gastric or duodenal ulcer and hypertension. This contraindication, documented in classical and reference sources, reflects the potent bitter stimulating properties of the herb on gastric secretion, which may exacerbate acid-related mucosal conditions.
As a traditional Chinese medicinal material, Radix Gentianae Macrophyllae faces significant challenges in quality control due to frequent adulteration and substitution. This is a documented safety-relevant concern, as substituted materials may carry different chemical profiles and different risk/benefit characteristics. To ensure quality, the Chinese Pharmacopoeia recommends that, in addition to the HPLC method, morphological, microscopic, and thin-layer chromatography identification techniques should also be performed; the total content of gentiopicroside and loganic acid in qualified samples should be greater than 2.5%.
The metabolic profile of gentiopicroside after intravenous injection fits a two-compartment model, whereas oral administration of decoctions fits a one-compartment model. After oral administration of gentiopicroside alone, it is absorbed quickly with a half-life of approximately 3.35 hours. Some species of Gentiana inhibit monoamine oxidase (MAO) and acetylcholinesterase in vitro. The clinical significance of MAO inhibition in humans at doses used in herbal preparations has not been well-characterised in the indexed literature. Caution regarding co-administration with MAO inhibitors or acetylcholinesterase-targeting drugs is warranted based on in vitro findings.
Because Radix Gentianae Macrophyllae (Qinjiao) is officially sourced from four distinct Gentiana species, and because these differ in their chemical profiles, the identity verification of commercial preparations is pharmacopoeially significant. Research has established a procedure for identification of large-leaved gentian (Gentiana macrophylla Pall.) using thin-layer chromatography (TLC).
The existing safety information for G. macrophylla is largely derived from traditional use records and animal experiments. Systematic clinical safety studies (adverse event monitoring in controlled trials, drug-drug interaction studies in humans, or reproductive safety assessments) have not been identified in the indexed scientific literature specific to this species. Proper toxic evaluation is described in the literature as indispensable to guarantee the safety, efficacy, and eligibility for medical use.
Health conditions that Large-leaf gentian may help support.
Large-leaf gentian (Gentiana macrophylla, Qin Jiao) is used in Traditional Chinese Medicine for hepatobiliary complaints including hepatitis, cholecystitis, and biliary dyskinesia. Listed in the Chinese Pharmacopoeia, its bitter iridoid glycosides have choleretic and anti-inflammatory activity in preclinical studies.
Body systems that Large-leaf gentian may help support.
Go back